Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

NCT02221869
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
Xyrem
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Long Beach, California • Orange, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 29, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer

NCT06043713
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, T-cell Receptor-engineered T-cells
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

FT576 in Subjects With Multiple Myeloma

NCT05182073
View directory record Official record
Conditions
Multiple Myeloma, Myeloma
Interventions
FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT02355886
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Gabapentin, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

NCT00864760
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 29, 2026, 5:03 PM EDT
Terminated Phase 4 Interventional Results available

PROUD Study - Preventing Opioid Use Disorders

NCT04766996
View directory record Official record
Conditions
Anesthesia, Opioid Use
Interventions
Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
Behavioral · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

NCT00573261
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380
View directory record Official record
Conditions
Healthy
Interventions
efavirenz, fenofibric acid 105 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217
View directory record Official record
Conditions
Amyloid-beta
Interventions
Sodium Oxybate, Sleep deprivation
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 29, 2026, 5:03 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 29, 2026, 5:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

NCT07225985
View directory record Official record
Conditions
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 29, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

Efficacy of Methylprednisolone for Pain Control After ACL Repair

NCT07158476
View directory record Official record
Conditions
ACL Surgery, Pain Management
Interventions
Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 29, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

The NaBu Effect on Menstruation in Women

NCT06653426
View directory record Official record
Conditions
Menstrual Symptoms
Interventions
Sodium Butyrate (NaBu)
Dietary Supplement
Lead sponsor
Magdy Milad, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00984542
View directory record Official record
Conditions
Lung Cancer
Interventions
bendamustine hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Elizabethtown, Kentucky • Germantown, Tennessee • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

NCT01216683
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Bendamustin, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
227
States / cities
Greenbrae, California • Salinas, California • Stanford, California + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 29, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Pregabalin for the Treatment of Vulvodynia

NCT00853229
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis
Interventions
pregabalin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Obinutuzumab, Bendamustine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 29, 2026, 5:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 29, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

NCT01533753
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gabapentin, Venlafaxine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01412879
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
204
States / cities
Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 29, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6

NCT00000303
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Baclofen
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 29, 2026, 5:03 PM EDT
Not listed Phase 4 Interventional

Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome

NCT02424695
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Gabapentin Enacarbil (GEn), Placebo
Drug
Lead sponsor
Cleveland Sleep Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 29, 2026, 5:03 PM EDT